James Johnson
Director/Board Member at ATHIRA PHARMA, INC.
Net worth: 9 600 $ as of 2024-04-29
Profile
James Algot Johnson is an Independent Director at Athira Pharma, Inc. He previously worked as Vice President-Finance at Immunex Corp.
from 1988 to 1994, Chief Financial Officer, Treasurer & Senior VP at AmpliPhi Biosciences Corp.
from 1994 to 2001, CFO, Secretary, Treasurer & Executive VP at ZymoGenetics, Inc. from 2007 to 2010, CFO & Principal Accounting Officer at NanoString Technologies, Inc. from 2012 to 2017, and Chief Financial Officer at Nohla Therapeutics, Inc. from 2018 to 2019.
He also worked as Chief Financial Officer & Senior Vice President at Relypsa, Inc. from 2011 to 2012 and is currently the Chief Financial Officer at C3J Therapeutics, Inc. Mr. Johnson received his undergraduate degree from the University of Washington in 1979.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ATHIRA PHARMA, INC.
0.01% | 2024-05-23 | 5,000 ( 0.01% ) | 9 600 $ | 2024-04-29 |
James Johnson active positions
| Companies | Position | Start |
|---|---|---|
| ATHIRA PHARMA, INC. | Director/Board Member | 2020-07-31 |
Former positions of James Johnson
| Companies | Position | End |
|---|---|---|
Nohla Therapeutics, Inc.
 Nohla Therapeutics, Inc. BiotechnologyHealth Technology Nohla Therapeutics, Inc. developed cellular therapies for hematological disorders. The firm's products used without the need for HLA matching and promote hematopoietic recovery in patients at risk for neutropenia after intensive chemotherapy and/or radiation treatment for critical diseases. The company was founded by Colleen Delaney and was headquartered in Seattle, WA. | Director of Finance/CFO | 2019-07-31 |
| NANOSTRING TECHNOLOGIES, INC. | Director of Finance/CFO | 2017-12-30 |
| RELYPSA INC | Director of Finance/CFO | 2012-08-31 |
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Director of Finance/CFO | 2010-09-30 |
AmpliPhi Biosciences Corp.
 AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Director of Finance/CFO | 2001-01-31 |
Training of James Johnson
| University of Washington | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| NANOSTRING TECHNOLOGIES, INC. | Health Technology |
| ATHIRA PHARMA, INC. | Health Technology |
| Private companies | 6 |
|---|---|
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Health Technology |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Health Technology |
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Health Technology |
Relypsa, Inc.
 Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
Nohla Therapeutics, Inc.
Nohla Therapeutics, Inc. BiotechnologyHealth Technology Nohla Therapeutics, Inc. developed cellular therapies for hematological disorders. The firm's products used without the need for HLA matching and promote hematopoietic recovery in patients at risk for neutropenia after intensive chemotherapy and/or radiation treatment for critical diseases. The company was founded by Colleen Delaney and was headquartered in Seattle, WA. | Health Technology |
C3J Therapeutics, Inc.
 C3J Therapeutics, Inc. BiotechnologyHealth Technology C3J Therapeutics, Inc. operates as a biotechnology company. It focuses on the discovery and development of novel targeted antimicrobials-synthetic bacteriophage and antimicrobial peptides. The company was founded by Randal Eckert, Maxwell H. Anderson and Wenyuan Shi in 2005 and is headquartered in Marina del Rey, CA. | Health Technology |
- Stock Market
- Insiders
- James Johnson
